Showing results (131-140 of 150) with videos related to
Sort By:
Pageof 15
Blood|October 9, 1999
Lymphoproliferative syndrome with autoimmunity: A possible genetic basis for dominant expression of the clinical manifestationsF Rieux-Laucat, S Blachère, S Danielan, et al.Oncogene|September 15, 2015
The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease developmentA-L Joly, A Deepti, A Seignez, et al.Blood|August 15, 1996
Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter studyE Solary, B Witz, D Caillot, et al.Cell Death & Disease|July 27, 2013
Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanismsA Ali, O Bluteau, K Messaoudi, et al.Leukemia Research|December 20, 2011
Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?R Itzykson, S Thépot, O Beyne-Rauzy, et al.Leukemia Research|January 30, 2017
Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic diseaseM Annereau, C Willekens, L El Halabi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues MyeloblastiquesJ L Harousseau, B Witz, B Lioure, et al.Leukemia & Lymphoma|March 28, 1998
PreB1 (CD10-) acute lymphoblastic leukemia: immunophenotypic and genomic characteristics, clinical features and outcome in 38 adults and 26 children. The Groupe dEtude Immunologique des LeucémiesB Lenormand, M C Béné, J F Lesesve, et al.Leukemia Research|January 21, 2015
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome predictionF Ramos, S Thépot, L Pleyer, et al.Cell Death & Disease|October 5, 2012
CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse modelY Zhang, S Patel, H Abdelouahab, et al.Pageof 15